Baili Biopharma

Baili Biopharma is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-based therapies for oncology. The company utilizes its proprietary GNC (Guidance & Navigation Control) platform to create multi-specific antibodies and its Hi-Tide platform for advanced antibody-drug conjugates (ADCs). Their lead candidate, BL-B01D1, is a first-in-class bispecific ADC targeting EGFR and HER3, which is currently in global Phase 3 development following a multi-billion dollar partnership with Bristol Myers Squibb. Headquartered in Chengdu, China, with R&D operations in Seattle via its subsidiary SystImmune, Baili maintains fully integrated capabilities from drug discovery to GMP manufacturing. The company is publicly traded on the Shanghai Stock Exchange STAR Market and is recognized for its innovative approach to complex cancer targets.